Drug intelligence / Profile preview

Dronabinol MDI

Development stage: Discontinued
Lead developer: Abbott
Modality: Small Molecules
Administration: Inhalation

Overview

Dronabinol MDI is an inhaled formulation of synthetic delta-9-tetrahydrocannabinol (THC) developed by Solvay Pharmaceuticals in collaboration with Nektar Therapeutics. It was designed for the acute treatment of moderate to severe migraine headaches. By utilizing a pressurized metered dose inhaler, the drug aims to provide rapid systemic absorption and a faster onset of action compared to oral dronabinol (Marinol), bypassing first-pass liver metabolism. Dronabinol acts as an agonist at the cannabinoid CB1 receptors in the brain. The program reached Phase 2 clinical development (NCT00123201) but was ultimately discontinued following the acquisition of Solvay Pharmaceuticals by Abbott.

Other names: Inhaled dronabinolDronabinol metered dose inhaler

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on Dronabinol MDI.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dronabinol MDI.

Explore the full profile